PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[18F]F-L-DOPA

被引：20
作者：
Pestourie, Carine [1 ,2 ]
Theze, Benoit [1 ,2 ]
Kuhnast, Bertrand [2 ]
Le Helleix, Stephane [2 ]
Gombert, Karine [1 ,2 ]
Dolle, Frederic [2 ]
Tavitian, Bertrand [1 ,2 ]
Duconge, Frederic [1 ,2 ]
机构：
[1] INSERM, Equipe Imagerie Express Genes, U803, F-91401 Orsay, France
[2] CEA, Inst Imagerie BioMed, Serv Hosp Frederic Joliot, Lab Imagerie Mol Expt, F-91401 Orsay, France
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2010年 / 37卷 / 01期
关键词：
Small animal PET imaging; 6-[F-18]F-L-DOPA; Medullary thyroid carcinoma; MEN2A transgenic mice; ENDOCRINE NEOPLASIA TYPE-2; NEUROENDOCRINE TUMORS; RET PROTOONCOGENE; CANCER; F-18-DOPA; INHIBITION; KINETICS; TARGET; DOPA;
D O I：
10.1007/s00259-009-1208-8
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
6-[F-18]Fluoro-3,4-dihydroxy-L-phenylalanine (6-[F-18]F-L-DOPA) is increasingly used for PET imaging of neuroendocrine tumours. In this study, we investigated the use of 6-[F-18]F-L-DOPA to detect and to monitor the progression of medullary thyroid carcinoma (MTC) in a genetically engineered mouse model of multiple endocrine neoplasia type 2A (MEN2A). Dynamic [F-18]FDG and 6-[F-18]F-L-DOPA small animal PET scans were acquired during 60 or 90 min in 8- to 20-month-old MEN2A transgenic mice. The kinetics of 6-[F-18]F-L-DOPA, standardized uptake values (SUV) at 60 min and tumour volumes were recorded. The detection of MTCs using PET was confirmed by autopsy and histological analysis. 6-[F-18]F-L-DOPA performs better than [F-18]FDG for MTC detection in this transgenic mouse model. Uptake kinetics of 6-[F-18]F-L-DOPA in MTCs are very different between mice but, in all cases, high contrast could be observed. Furthermore, 6-[F-18]F-L-DOPA can detect tumours with sizes (1.8 mm(3)) that are near the resolution limit of PET, whereas they were undetectable by autopsy at the macroscopic level. 6-[F-18]F-L-DOPA PET imaging can monitor the progression of MTCs in a genetically engineered mouse model.
引用
收藏
页码：58 / 66
页数：9
相关论文
共 26 条
[1]   Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma [J].
Beuthien-Baumann, B. ;
Strumpf, A. ;
Zessin, J. ;
Bredow, J. ;
Kotzerke, J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (10) :1604-1609
[2]  
Dolle F, 1998, J LABELLED COMPD RAD, V41, P105, DOI 10.1002/(SICI)1099-1344(199802)41:2<105::AID-JLCR65>3.0.CO
[3]  
2-H
[4]   Time profile of cerebral [18F]6-fluoro-L-dopa metabolites in nonhuman primate: Implications for the kinetics of therapeutic L-dopa [J].
Endres, CJ ;
DeJesus, OT ;
Uno, H ;
Doudet, DJ ;
Nickles, RJ ;
Holden, JE .
FRONTIERS IN BIOSCIENCE, 2004, 9 :505-512
[5]  
Ezzat S, 2005, CLIN CANCER RES, V11, P1336
[6]   Multiple endocrine neoplasia type 2 and RET:: from neoplasia to neurogenesis [J].
Hansford, JR ;
Mulligan, LM .
JOURNAL OF MEDICAL GENETICS, 2000, 37 (11) :817-827
[7]   Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors [J].
Hoegerle, S ;
Altehoefer, C ;
Ghanem, N ;
Koehler, G ;
Waller, CF ;
Scheruebl, H ;
Moser, E ;
Nitzsche, E .
RADIOLOGY, 2001, 220 (02) :373-380
[8]   6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors:: Basic aspects and emerging clinical applications [J].
Jager, Pieter L. ;
Chirakal, Raman ;
Marriott, Christopher J. ;
Brouwers, Adrienne H. ;
Koopmans, Klaas Pieter ;
Gulenchyn, Karen Y. .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (04) :573-586
[9]   Genetic alterations in thyroid cancer: The role of mouse models [J].
Knostman, K. A. B. ;
Jhiang, S. M. ;
Capen, C. C. .
VETERINARY PATHOLOGY, 2007, 44 (01) :1-14
[10]   18F-Dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer:: Relation to tumor differentiation [J].
Koopmans, Klaas P. ;
de Groot, Jan Willem B. ;
Plukker, John T. M. ;
de Vries, Elisabeth G. E. ;
Kema, Ido P. ;
Sluiter, Wim J. ;
Jager, Pieter L. ;
Links, Thera P. .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (04) :524-531
123